A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 May 2017

At a glance

  • Drugs FRM 0334 (Primary)
  • Indications Dementia; Neurodegenerative disorders
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors FORUM Pharmaceuticals
  • Most Recent Events

    • 10 Apr 2017 This trial has been completed in united kingdom (end date: 2016-06-24) according to European Clinical Trials Database record.
    • 04 Oct 2016 This trial was completed in Netherlands, according to European Clinical Trials Database.
    • 30 Jul 2016 This trial was completed in Belgium (end date: 2016-07-24) according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top